• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PPM1D 通过抑制综合应激反应抑制 p53 依赖性的转录激活和细胞死亡。

PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response.

机构信息

Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.

Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.

出版信息

Nat Commun. 2022 Dec 1;13(1):7400. doi: 10.1038/s41467-022-35089-5.

DOI:10.1038/s41467-022-35089-5
PMID:36456590
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9715646/
Abstract

The p53 transcription factor is a master regulator of cellular stress responses inhibited by repressors such as MDM2 and the phosphatase PPM1D. Activation of p53 with pharmacological inhibitors of its repressors is being tested in clinical trials for cancer therapy, but efficacy has been limited by poor induction of tumor cell death. We demonstrate that dual inhibition of MDM2 and PPM1D induces apoptosis in multiple cancer cell types via amplification of the p53 transcriptional program through the eIF2α-ATF4 pathway. PPM1D inhibition induces phosphorylation of eIF2α, ATF4 accumulation, and ATF4-dependent enhancement of p53-dependent transactivation upon MDM2 inhibition. Dual inhibition of p53 repressors depletes heme and induces HRI-dependent eIF2α phosphorylation. Pharmacological induction of eIF2α phosphorylation synergizes with MDM2 inhibition to induce cell death and halt tumor growth in mice. These results demonstrate that PPM1D inhibits both the p53 network and the integrated stress response controlled by eIF2α-ATF4, with clear therapeutic implications.

摘要

p53 转录因子是细胞应激反应的主要调节因子,受 MDM2 和磷酸酶 PPM1D 等抑制剂的抑制。用其抑制剂的药理学抑制剂激活 p53 正在临床试验中用于癌症治疗,但疗效受到肿瘤细胞死亡诱导不良的限制。我们证明,通过 eIF2α-ATF4 途径放大 p53 转录程序,双重抑制 MDM2 和 PPM1D 可诱导多种癌细胞类型的细胞凋亡。PPM1D 抑制诱导 eIF2α 的磷酸化、ATF4 的积累以及 ATF4 依赖性增强 MDM2 抑制后的 p53 依赖性反式激活。p53 抑制剂的双重抑制会耗尽血红素并诱导 HRI 依赖性 eIF2α 磷酸化。eIF2α 磷酸化的药理学诱导与 MDM2 抑制协同作用,可诱导细胞死亡并阻止小鼠肿瘤生长。这些结果表明,PPM1D 抑制 p53 网络和由 eIF2α-ATF4 控制的综合应激反应,具有明确的治疗意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/31b11d99714d/41467_2022_35089_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/06930a73d7e8/41467_2022_35089_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/2a1c62409b26/41467_2022_35089_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/d6bd1283c2ca/41467_2022_35089_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/76b26e59391c/41467_2022_35089_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/31b11d99714d/41467_2022_35089_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/06930a73d7e8/41467_2022_35089_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/2a1c62409b26/41467_2022_35089_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/d6bd1283c2ca/41467_2022_35089_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/76b26e59391c/41467_2022_35089_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e7/9715646/31b11d99714d/41467_2022_35089_Fig5_HTML.jpg

相似文献

1
PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response.PPM1D 通过抑制综合应激反应抑制 p53 依赖性的转录激活和细胞死亡。
Nat Commun. 2022 Dec 1;13(1):7400. doi: 10.1038/s41467-022-35089-5.
2
Phosphorylation of eIF2α suppresses cisplatin-induced p53 activation and apoptosis by attenuating oxidative stress via ATF4-mediated HO-1 expression in human renal proximal tubular cells.磷酸化 eIF2α 通过 ATF4 介导的 HO-1 表达减轻氧化应激,从而抑制顺铂诱导的人肾近端肾小管细胞中 p53 的激活和凋亡。
Int J Mol Med. 2017 Dec;40(6):1957-1964. doi: 10.3892/ijmm.2017.3181. Epub 2017 Oct 10.
3
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.GSK2830371对野生型p53诱导磷酸酶1(WIP1/PPM1D)的化学抑制作用以p53依赖的方式增强了对MDM2抑制剂的敏感性。
Mol Cancer Ther. 2016 Mar;15(3):379-91. doi: 10.1158/1535-7163.MCT-15-0651. Epub 2016 Feb 1.
4
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.TP53 野生型/PPM1D 突变弥漫性内在脑桥胶质瘤对 MDM2 拮抗剂敏感。
Acta Neuropathol Commun. 2021 Nov 3;9(1):178. doi: 10.1186/s40478-021-01270-y.
5
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.WIP1磷酸酶的抑制使乳腺癌细胞对基因毒性应激和MDM2拮抗剂Nutlin-3敏感。
Oncotarget. 2016 Mar 22;7(12):14458-75. doi: 10.18632/oncotarget.7363.
6
Involvement of p38 in signal switching from autophagy to apoptosis via the PERK/eIF2α/ATF4 axis in selenite-treated NB4 cells.亚硒酸盐处理的NB4细胞中p38通过PERK/eIF2α/ATF4轴参与自噬到凋亡的信号转换。
Cell Death Dis. 2014 May 29;5(5):e1270. doi: 10.1038/cddis.2014.200.
7
A sustained deficiency of mitochondrial respiratory complex III induces an apoptotic cell death through the p53-mediated inhibition of pro-survival activities of the activating transcription factor 4.线粒体呼吸复合物III的持续缺乏通过p53介导的对激活转录因子4的促生存活性的抑制诱导凋亡性细胞死亡。
Cell Death Dis. 2014 Nov 6;5(11):e1511. doi: 10.1038/cddis.2014.469.
8
Mdm2 inhibition of p53 induces E2F1 transactivation via p21.Mdm2对p53的抑制作用通过p21诱导E2F1反式激活。
Oncogene. 2002 Jun 27;21(28):4414-21. doi: 10.1038/sj.onc.1205541.
9
PPM1D activity promotes the replication stress caused by cyclin E1 overexpression.PPM1D 活性促进了 cyclin E1 过表达引起的复制应激。
Mol Oncol. 2024 Jan;18(1):6-20. doi: 10.1002/1878-0261.13433. Epub 2023 Oct 16.
10
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.Nutlin-3a与Wip1抑制剂协同诱导p53活性。
Oncotarget. 2016 May 31;7(22):31623-38. doi: 10.18632/oncotarget.9302.

引用本文的文献

1
The ubiquitin ligase Triad1 influences myeloid leukemogenesis by regulating the integrated stress response.泛素连接酶Triad1通过调节整合应激反应影响髓系白血病发生。
J Biol Chem. 2025 Jul 16;301(8):110484. doi: 10.1016/j.jbc.2025.110484.
2
Gain-of-function PPM1D mutations attenuate ischemic stroke.功能获得性PPM1D突变可减轻缺血性中风。
Cell Death Differ. 2025 May 21. doi: 10.1038/s41418-025-01523-6.
3
Safety profile of sikamat virus and its oncolytic potential in leukemic cells and cancer stem cells.西卡马特病毒的安全性概况及其在白血病细胞和癌症干细胞中的溶瘤潜力。

本文引用的文献

1
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.在日本实体瘤患者中的安全性和药代动力学研究:Milademetan,一种 MDM2 抑制剂的 I 期研究。
Cancer Sci. 2021 Jun;112(6):2361-2370. doi: 10.1111/cas.14875. Epub 2021 May 2.
2
AP-1 subunits converge promiscuously at enhancers to potentiate transcription.AP-1 亚基杂乱无章地聚集在增强子上,增强转录。
Genome Res. 2021 Apr;31(4):538-550. doi: 10.1101/gr.267898.120. Epub 2021 Mar 5.
3
P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9.
Sci Rep. 2025 Apr 22;15(1):13817. doi: 10.1038/s41598-025-96061-z.
4
Mutation as a Distinct Feature of Myeloid Neoplasms in B-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis.B细胞非霍奇金淋巴瘤患者髓系肿瘤的独特特征——突变:一项回顾性分析
Cancers (Basel). 2025 Mar 31;17(7):1185. doi: 10.3390/cancers17071185.
5
Affinity-based protein profiling of MDM2 inhibitor Navtemadlin.基于亲和力的MDM2抑制剂Navtemadlin的蛋白质谱分析。
Chem Sci. 2025 Mar 12;16(16):6886-6894. doi: 10.1039/d5sc00120j. eCollection 2025 Apr 16.
6
Harnessing p53 for targeted cancer therapy: new advances and future directions.利用p53进行靶向癌症治疗:新进展与未来方向。
Transcription. 2025 Feb;16(1):3-46. doi: 10.1080/21541264.2025.2452711. Epub 2025 Mar 3.
7
Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes.DNMT3A 和 TET2 的功能丧失性突变导致动脉粥样硬化加速和一致的巨噬细胞表型。
Nat Cardiovasc Res. 2023 Sep;2(9):805-818. doi: 10.1038/s44161-023-00326-7. Epub 2023 Sep 4.
8
Determinants of p53 DNA binding, gene regulation, and cell fate decisions.p53 基因的 DNA 结合、基因调控和细胞命运决定的决定因素。
Cell Death Differ. 2024 Jul;31(7):836-843. doi: 10.1038/s41418-024-01326-1. Epub 2024 Jun 29.
9
Non-Canonical STING-PERK Pathway Modulation of Cellular Senescence and Therapeutic Response in Sepsis-Associated Acute Kidney Injury.非经典STING-PERK通路对脓毒症相关性急性肾损伤中细胞衰老和治疗反应的调控
Inflammation. 2025 Apr;48(2):696-712. doi: 10.1007/s10753-024-02081-8. Epub 2024 Jun 24.
10
Putative Molecular Mechanisms Underpinning the Inverse Roles of Mitochondrial Respiration and Heme Function in Lung Cancer and Alzheimer's Disease.线粒体呼吸与血红素功能在肺癌和阿尔茨海默病中的相反作用的潜在分子机制
Biology (Basel). 2024 Mar 14;13(3):185. doi: 10.3390/biology13030185.
通过 ERK1/2 和 CDK9 对 ATF4 的转录调节,使突变型 p53 的肿瘤中 p53 通路部分恢复,且不依赖 p53。
Neoplasia. 2021 Mar;23(3):304-325. doi: 10.1016/j.neo.2021.01.004. Epub 2021 Feb 11.
4
Characteristics and Biomarkers of Ferroptosis.铁死亡的特征与生物标志物
Front Cell Dev Biol. 2021 Jan 21;9:637162. doi: 10.3389/fcell.2021.637162. eCollection 2021.
5
The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir.艾滋病病毒蛋白酶抑制剂奈非那韦的抗癌特性
Cancers (Basel). 2020 Nov 19;12(11):3437. doi: 10.3390/cancers12113437.
6
Transcription and Translation Inhibitors in Cancer Treatment.癌症治疗中的转录和翻译抑制剂
Front Chem. 2020 Apr 21;8:276. doi: 10.3389/fchem.2020.00276. eCollection 2020.
7
The switch-like expression of heme-regulated kinase 1 mediates neuronal proteostasis following proteasome inhibition.血红素调节激酶 1 的开关样表达介导蛋白酶体抑制后的神经元蛋白质稳态。
Elife. 2020 Apr 24;9:e52714. doi: 10.7554/eLife.52714.
8
SynergyFinder 2.0: visual analytics of multi-drug combination synergies.SynergyFinder 2.0:多药物组合协同作用的可视化分析。
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493. doi: 10.1093/nar/gkaa216.
9
Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway.线粒体应激通过 OMA1-DELE1-HRI 途径传递到细胞质。
Nature. 2020 Mar;579(7799):427-432. doi: 10.1038/s41586-020-2078-2. Epub 2020 Mar 4.
10
Ferroptosis: past, present and future.铁死亡:过去、现在和未来。
Cell Death Dis. 2020 Feb 3;11(2):88. doi: 10.1038/s41419-020-2298-2.